title: Adverse events post smallpox-vaccination: insights from tail scarification infection in mice with Vaccinia virus.
abstract: Adverse events upon smallpox vaccination with fully-replicative strains of Vaccinia virus (VACV) comprise an array of clinical manifestations that occur primarily in immunocompromised patients leading to significant host morbidity/mortality. The expansion of immune-suppressed populations and the possible release of Variola virus as a bioterrorist act have given rise to concerns over vaccination complications should more widespread vaccination be reinitiated. Our goal was to evaluate the components of the host immune system that are sufficient to prevent morbidity/mortality in a murine model of tail scarification, which mimics immunological and clinical features of smallpox vaccination in humans. Infection of C57BL/6 wild-type mice led to a strictly localized infection, with complete viral clearance by day 28 p.i. On the other hand, infection of T and B-cell deficient mice (Rag1(-/-)) produced a severe disease, with uncontrolled viral replication at the inoculation site and dissemination to internal organs. Infection of B-cell deficient animals (µMT) produced no mortality. However, viral clearance in µMT animals was delayed compared to WT animals, with detectable viral titers in tail and internal organs late in infection. Treatment of Rag1(-/-) with rabbit hyperimmune anti-vaccinia serum had a subtle effect on the morbidity/mortality of this strain, but it was effective in reduce viral titers in ovaries. Finally, NUDE athymic mice showed a similar outcome of infection as Rag1(-/-), and passive transfer of WT T cells to Rag1(-/-) animals proved fully effective in preventing morbidity/mortality. These results strongly suggest that both T and B cells are important in the immune response to primary VACV infection in mice, and that T-cells are required to control the infection at the inoculation site and providing help for B-cells to produce antibodies, which help to prevent viral dissemination. These insights might prove helpful to better identify individuals with higher risk of complications after infection with poxvirus.
authors.affiliation: Laboratório de Vírus, Departamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Bruno E F
authors.initials: BE
authors.lastname: Mota
authors.forename: Nadia
authors.initials: N
authors.lastname: Gallardo-Romero
authors.forename: Giliane
authors.initials: G
authors.lastname: Trindade
authors.forename: M Shannon
authors.initials: MS
authors.lastname: Keckler
authors.forename: Kevin
authors.initials: K
authors.lastname: Karem
authors.forename: Darin
authors.initials: D
authors.lastname: Carroll
authors.forename: Marco A
authors.initials: MA
authors.lastname: Campos
authors.forename: Leda Q
authors.initials: LQ
authors.lastname: Vieira
authors.forename: Flávio G
authors.initials: FG
authors.lastname: da Fonseca
authors.forename: Paulo C P
authors.initials: PC
authors.lastname: Ferreira
authors.forename: Cláudio A
authors.initials: CA
authors.lastname: Bonjardim
authors.forename: Inger K
authors.initials: IK
authors.lastname: Damon
authors.forename: Erna G
authors.initials: EG
authors.lastname: Kroon
mesh_terms: D056704:Adaptive Immunity / Q000276:immunology; D019264:Adoptive Transfer; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D016207:Cytokines / Q000172:deficiency; D018398:Homeodomain Proteins / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D007700:Kinetics; D008212:Lymphocyte Depletion; D051379:Mice; D008810:Mice, Inbred C57BL; D009928:Organ Specificity; D011817:Rabbits; D012899:Smallpox / Q000276:immunology* / Q000517:prevention & control; D013623:Tail / Q000276:immunology* / Q000821:virology*; D014611:Vaccination / Q000009:adverse effects*; D014615:Vaccinia / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control / Q000821:virology*; D014616:Vaccinia virus / Q000276:immunology* / Q000502:physiology; D014779:Virus Replication / Q000276:immunology
chemical_list: D016207:Cytokines; D018398:Homeodomain Proteins; D018836:Inflammation Mediators; C064658:RAG-1 protein